Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EBITDA (2019 - 2025)

Historic EBITDA for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$976000.0.

  • Cyclerion Therapeutics' EBITDA fell 3499.31% to -$976000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year increase of 3472.83%. This contributed to the annual value of -$3.6 million for FY2024, which is 7198.67% up from last year.
  • Cyclerion Therapeutics' EBITDA amounted to -$976000.0 in Q3 2025, which was down 3499.31% from -$1.7 million recorded in Q2 2025.
  • Over the past 5 years, Cyclerion Therapeutics' EBITDA peaked at $502000.0 during Q4 2024, and registered a low of -$16.2 million during Q2 2021.
  • Over the past 5 years, Cyclerion Therapeutics' median EBITDA value was -$4.5 million (recorded in 2022), while the average stood at -$6.5 million.
  • In the last 5 years, Cyclerion Therapeutics' EBITDA surged by 12796.66% in 2024 and then tumbled by 3499.31% in 2025.
  • Quarter analysis of 5 years shows Cyclerion Therapeutics' EBITDA stood at -$14.3 million in 2021, then skyrocketed by 68.93% to -$4.5 million in 2022, then surged by 59.71% to -$1.8 million in 2023, then surged by 127.97% to $502000.0 in 2024, then tumbled by 294.42% to -$976000.0 in 2025.
  • Its EBITDA stands at -$976000.0 for Q3 2025, versus -$1.7 million for Q2 2025 and -$1.5 million for Q1 2025.